German biotech company BioVisioN AG signed an agreement with Abbott to collaborate on research relating to the discovery of novel biomarkers for lung cancer. According to the agreement, BioVisioN will be paid to analyze biological samples provided by Abbott to discover tumor biomarkers, and, if successful, milestones and royalty payments.

Dr. Rainer Voegeli, Chief Business Officer of BioVisioN AG, says:

"Our early activities in the area of proteomics and peptidomics are now paying off. We are the world leader in peptide biomarker discovery with our patent protected technologies. We are proud that Abbott has chosen us as a partner."

BioVisioN AG specializes in the identification of disease-relevant peptides and proteins using Peptidomics and Differential Peptide Display. The company was founded in 1997 and today employs 45 people. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organization.